In a major healthcare collaboration, Coal India Limited (CIL) and Indraprastha Apollo Hospitals have signed a Memorandum of Understanding (MoU) to bolster thalassemia treatment for children. The partnership, under CIL’s Thalassemia Bal Seva Yojna initiative, aims to expand support for children suffering from thalassemia and severe aplastic anemia who require bone marrow transplants. The initiative, supported by the Ministry of Health & Family Welfare and Thalassemics India, represents a significant step in improving care for young patients in India.

Dr. Gaurav Kharya, Director of the Centre for Bone Marrow Transplant & Cellular Therapy at Indraprastha Apollo Hospitals, highlighted the transformative potential of the partnership. “This collaboration marks a pivotal moment in our mission to transform the lives of children battling thalassemia and severe aplastic anemia. With the support of Coal India, we are pushing boundaries to offer these children not just hope but the promise of a healthier, brighter future,” said Dr. Kharya.

The initiative is expected to significantly enhance both the accessibility and quality of treatment available to children affected by these serious blood disorders. By combining Coal India’s commitment to corporate social responsibility with Indraprastha Apollo’s cutting-edge medical expertise, the partnership is poised to make a meaningful impact on young patients’ lives across the country.
Indraprastha Apollo Hospitals: A Leader in Medical Innovation
Indraprastha Apollo Hospitals, India's first Joint Commission International (JCI) accredited hospital, has long been a pioneer in healthcare. Established as a joint venture between the Government of Delhi and Apollo Hospitals Enterprise Limited in 1996, the hospital has become a leading institution, offering a wide array of specialized services.

The hospital’s Centre for Bone Marrow Transplant & Cellular Therapy is one of the country’s fastest-growing facilities for bone marrow transplants (BMT). The center is not only focused on optimizing transplant outcomes but is also advancing cutting-edge therapies, including CAR T-cell therapy and gene therapy for various hematological conditions.

Indraprastha Apollo continues to be at the forefront of medical technology, most recently introducing the ZAP-X Gyroscopic Radiosurgery Platform for non-invasive brain tumor treatment. This revolutionary technology offers patients a safer and more comfortable alternative to traditional brain surgery. Additionally, the hospital has introduced the RADIXACT-X9, which combines imaging and treatment delivery to precisely target various cancers, further cementing its position as a leader in innovative cancer care.

With over 57 specialties, 300+ specialists, and state-of-the-art diagnostic and surgical facilities, Indraprastha Apollo is recognized as one of India’s top hospitals. It has consistently ranked among the top 10 hospitals in the country, according to The Week's annual survey.

A Shared Commitment to Health and Compassion
The MoU between Coal India Limited and Indraprastha Apollo Hospitals underscores both organizations' dedication to compassionate, high-quality healthcare. As the partnership moves forward, it holds the potential to offer life-changing treatment to thousands of children, providing not just medical care but a brighter future for those affected by thalassemia and severe aplastic anemia.